Artesunate shows potent anti-tumor activity in B-cell lymphoma
Artesunate
Dihydroartemisinin
B-cell lymphoma
DOI:
10.1186/s13045-018-0561-0
Publication Date:
2018-02-20T00:30:11Z
AUTHORS (14)
ABSTRACT
Although chemo-immunotherapy has led to an improved overall survival for most B-cell lymphoma types, relapsed and refractory disease remains a challenge. The malaria drug artesunate previously been identified as growth suppressor in some cancer types was tested new treatment option lymphoma.We included sensitivity screen B cell lines. preclinical properties of single agent vitro 18 lines representing different histologies vivo aggressive xenograft model, using NSG mice. Artesunate-treated were analyzed by functional assays, gene expression profiling, protein identify the mechanism action.Drug screening highly potent anti-lymphoma drug. Artesunate induced suppression cells with IC50 comparable concentrations measured serum from artesunate-treated patients, while leaving normal B-cells unaffected. markedly inhibited tumor model. Gene analysis endoplasmic reticulum (ER) stress unfolded response affected pathways artesunate-induced ER markers ATF-4 DDIT3 specifically upregulated malignant B-cells, but not B-cells. In addition, significantly suppressed metabolism, affecting both respiration glycolysis.Artesunate demonstrated apoptosis-inducing effects across broad range vitro, prominent activity vivo, suggesting it be relevant lymphoma.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (51)
CITATIONS (70)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....